Humoral activity was analyzed using ACCESS SARS-CoV-2 (Beckman Coulter Inc., Brea, CA, USA)a two-step enzyme chemiluminescent immunoassay (CLIA). both cohorts had been higher in convalescents (both before booster and 21 times after). The IgG titers had been subtly low in COVID-19 convalescents than in na?ve but without statistical significance. Data on cell-mediated immunity are scarce, especially with regard to the general population. A better understanding of the complexity of the immune response to SARS-CoV-2 could contribute to developing more effective vaccination strategies. Keywords: COVID-19, SARS-CoV-2, immune response, vaccinations, T-cell immune response, immunoglobulin G, interferon-gamma release tests, humoral immunity, cellular immunity 1. BRD4770 Introduction COVID-19 (Coronavirus Disease 2019) is a highly contagious illness caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), an unknown earlier pathogen belonging to the broad and diverse family of [1,2]. It emerged at the end of 2019 in Wuhan, and within just a few weeks it spread throughout the world. Speed of transmission and its severe medical, social, and economic consequences led the World Health Organization (WHO) to the decision to pronounce, on 11 March 2020, COVID-19 a pandemic [3]. As BRD4770 of 8 September 2022, SARS-CoV-2 has contributedaccording to the official datato 603 711 760 BRD4770 confirmed cases and 6 484 136 deaths worldwide [4]. Today, over 2.5 years since the first case was reported in China, the COVID-19 pandemic is far from over. Moreover, its complex and long-term implications still constitute a great challenge for public health, the global economy, and politics [5]. Since the pandemics beginning, intensive research has been conductedboth on individual and population levelson the changing SARS-CoV-2 molecular structure and properties of circulating and emerging variants in terms of their transmissibility, impact on immunity, and severity of infection they cause [6,7]. Simultaneously, numerous trials have BRD4770 been performed to understand different manifestations and courses of COVID-19 (depending on the variant that caused it) and find the most optimal methods of prevention and treatment [8,9]. A significant breakthrough in preventing the virus spread and altering the pandemic trajectory the world sought was achieved in the development and rollout of COVID-19 vaccines [10,11]. BRD4770 The first vaccines outside clinical trials were administered in the United Kingdom on 8 December 2020 [12]. The first products available on the market were based on using part of viral mRNA containing nucleoside-modified RNA (modRNA) in lipid nanoparticles, encoding the SARS-CoV-2 full-length spike glycoprotein (mRNA-1273, Moderna; BNT162b2, Pfizer/BioNTech; BNT). Another vaccine type available for the public at that time was based on the replication-deficient chimpanzee adenoviral vector, containing the SARS-CoV-2 structural surface glycoprotein antigen gene [7,13,14] (ChAdOx1-S (recombinant), the Oxford/AstraZeneca; ChAd) [15,16]. All products mentioned above were approved for use as a two-dose primary course. Although vaccination is still considered the most effective defense strategy against SARS-CoV-2, multiple long-term follow-ups of vaccinated individuals conducted within clinical trials and real-world settings revealed that immune response to COVID-19 is waning over time [17,18,19]. Decreasing immunity has also been observed in individuals with COVID-19 history [20]. Moreover, numerous epidemiological studies report re-infections in vaccinated na?ve subjects and both vaccinated and non-vaccinated convalescents [21,22]. In addition, a growing body of evidence indicates that particular population groups mount a limited or undetectable immune response to SARS-CoV-2 vaccines [23]. Low or non-responsiveness to COVID-19 inoculation can be related to, i.a., genetics, overall physical and mental health (i.a., stress), immune status, and presence of particular conditions (i.a., autoimmune and inflammatory diseases), such as advanced age and immunosenescence [23,24,25]. Those observations led to the introduction of a booster dose of the vaccineto restore the protection against COVID-19-related serious outcomes. According to the current recommendations, it should be administered, depending on the product received during the initial series, optimally 4C6 months after completing the primary vaccination course [26,27,28]. Although the homologous strategy is still considered standard practice, due to changes in public health vaccination policy, and problems with vaccines availability, starting from Spring 2021, many countries decided to apply a heterologous booster [29,30]. Such an approach was initially documented as augmenting immune responses with tolerable reactogenicity [31,32,33]. The Rabbit Polyclonal to Androgen Receptor (phospho-Tyr363) primary aim of active immunization.
Monthly Archives: November 2024
(c) Initial velocities (v0) derived from (b) were used to calculate the % of active cutinase remaining after conjugation (5 M cut-GFP, 0C5 M pNP-Q11)
(c) Initial velocities (v0) derived from (b) were used to calculate the % of active cutinase remaining after conjugation (5 M cut-GFP, 0C5 M pNP-Q11). fusion SC-514 proteins via a covalent active site-directed capture approach to afford protein-laden nanofibers. These nanofibers could be formulated to present precisely controlled amounts of protein antigen and acted as self-adjuvanting vaccines in mice. Cutinase-pNP reactions were site-selective, allowing antigens to be conjugated without disrupting their tertiary structures, making the approach broadly useful for developing protein-bearing supramolecular materials in a range of applications including immunotherapies. Adjuvants and delivery platforms that present properly folded protein antigens are important in the development of vaccines because they allow for broad immunogenicity in outbred populations compared with peptide vaccines, and because they can include conformational epitopes.[10] Supramolecular assemblies are gaining interest in this regard, because they can be functionalized with a high density of antigens, in some cases without perturbing antigen conformation SC-514 or self-assembly of the material. For example, supramolecular nanoparticle vaccines have been designed to contain both folded protein antigens and peptide antigens that mimic native epitope conformations.[7, 8, 11C13] -sheet-rich nanofibers of peptides and peptide amphiphiles can also act as self-adjuvanting vaccines,[1, 4, 6] and they have an additional advantage of being highly modular, allowing SC-514 the incorporation of multiple different molecular components with negligible compositional drift.[14,15] However, although a few instances of protein-bearing -sheet-rich nanofibers have been reported previously,[16C18] vaccine platforms developed from these materials have employed only peptide antigens to date, which lack any intentionally designed conformation. We developed a general approach to produce supramolecular assemblies containing properly folded proteins using green fluorescent protein (GFP) as a model antigen, and we characterized the materials ability to raise immune responses in mice. Proteins were attached to peptide nanofibers using the chemoselective reaction of cutinase fusion proteins with nanofiber-bound suicide pNP ligands (Figure 1aCb), an approach that has been used previously to conjugate proteins to solid surfaces,[19, 20] but not to construct soft materials. First, we synthesized pNP-Q11, a variant of the -sheet fibrillizing peptide QQKFQFQFEQQ (Q11)[15, 21, 22] having a pNP ligand on its N-terminus, by reacting cysteine-terminated Q11 with maleimido-penta(ethylene glycol)-ethyl-p-nitrophenyl phosphonate, which we also synthesized (Figure 1a, detailed methods in Supplemental Information). In parallel we designed and expressed in a fusion protein containing cutinase and green fluorescent protein domains separated by a flexible linker of glycine and serine residues (cut-GFP). In phosphate-buffered saline, pNP-Q11 self-assembled into individual nanofibers and bundles of nanofibers whose morphologies were similar to previously investigated Q11 materials (Figure 1c).[21, 22] The peptides maintained this fibrillar morphology following reaction with cutinase fusion proteins (Figure 1d), which indicated that the presence of a relatively large appended protein did not perturb Q11 fibrillization. Open in a separate window Figure 1 Protein-bearing self-assembled peptide nanofibersa) pNP-Q11. b) Schematic of the non-covalent assembly of Q11 and pNP-Q11 into nanofibers, and the subsequent covalent capture of cutinase-GFP by pNP-bearing Q11 nanofibers. c-d) TEM of pNP-Q11 nanofibers before (c) and after (d) conjugation with cut-GFP. One SC-514 of the advantages of supramolecular systems is that the relative amounts of different functional components in the final material can often Rabbit polyclonal to ACD be controlled simply by mixing specific combinations of precursor molecules and inducing self-assembly.[23C25] The phosphonate-cutinase system also lent itself to this modularity, as the amount of antigen coupled to the peptide nanofibers could be controlled by specifying the amount of pNP-Q11 co-assembled with non-functionalized Q11 (Figure 2). Protein conjugation was assessed both directly by measuring GFP fluorescence on sedimented nanofibers, and indirectly using a colorimetric assay for residual unreacted cutinase following conjugation. [26] GFP fluorescence additionally served as an indication of proper protein folding. Self-assembled Q11 peptide nanofibers bearing increasing amounts of co-assembled pNP-Q11 bound predictably increasing amounts of cut-GFP, whether measured from the fluorescence of bound GFP (Number 2a) or by residual cutinase activity (Number 2b, c). Q11 fibrils lacking pNP bound negligible amounts of cut-GFP non-specifically, whereas pNP-bearing fibrils incubated having a molar equivalent of cut-GFP bound the protein with about 80% effectiveness (Number 2a). A 3-collapse molar excess of cut-GFP led to nearly complete reaction of the pNP ligand (not shown). In this way, the amount of protein displayed within the fibrils could be controlled with precision in a simple, straightforward manner, by dosing pNP-Q11 into Q11 nanofibers and reacting them with a slight molar excess of cut-GFP. Importantly, the pNP-cutinase conjugation proceeded to the same degree whether cut-GFP was added to freshly dissolved pNP-Q11 or to peptide that had been allowed to assemble into more mature peptide.